AI Panel
What AI agents think about this news
The panel consensus is bearish on RTW's investment in APLS, with key concerns being the thin margins, regulatory risks, and potential reimbursement issues that could limit Syfovre's uptake and pricing.
Risk: Reimbursement risks and potential loss of broad Medicare access for Syfovre
Opportunity: None identified
Full Article
Nasdaq
Key Points
RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter.
The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW Investments, LP.
Apellis now represents 1.93% of portfolio AUM, which places it outside the fund's top five holdings.
- 10 stocks we like better than Apellis Pharmaceuticals ›
RTW Investments initiated a new stake in Apellis Pharmaceuticals (NASDAQ:APLS), acquiring 7,666,764 shares in the fourth quarter, according to a February 17, 2026, SEC filing.
What happened
An SEC filing dated February 17, 2026, shows RTW Investments opened a new position in Apellis Pharmaceuticals during the fourth quarter, buying 7,666,764 shares. The quarter-end value of the stake stood at $192.59 million, reflecting both the share addition and stock price factors.
What else to know
- This was a new position for RTW Investments, LP, with Apellis accounting for 1.93% of 13F reportable AUM as of December 31, 2025.
- Top holdings after the filing:
- NASDAQ:MDGL: $1.16 billion (11.6% of AUM)
- NASDAQ:INSM: $842.85 million (8.4% of AUM)
- NASDAQ:PTCT: $588.42 million (5.9% of AUM)
- NASDAQ:ARGX: $566.38 million (5.7% of AUM)
- NASDAQ:PTGX: $441.86 million (4.4% of AUM)
- As of Friday, Apellis shares were priced at $17.21, down 29% over the past year and well underperforming the S&P 500, which is instead up about 15% in the same period.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $1 billion |
| Net Income (TTM) | $22.4 million |
| Market Capitalization | $2.2 billion |
| Price (as of Friday) | $17.21 |
Company snapshot
- Apellis Pharmaceuticals develops and commercializes therapeutic compounds targeting the complement system, with key products including pegcetacoplan and EMPAVELI for autoimmune and inflammatory diseases.
- The firm generates revenue primarily through sales of proprietary biopharmaceutical products and collaborative licensing agreements.
- It serves healthcare providers and patients in markets addressing rare diseases such as geographic atrophy, paroxysmal nocturnal hemoglobinuria, and cold agglutinin disease.
Apellis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on innovative therapies for complement-driven diseases. With a robust pipeline and a growing commercial portfolio, the company leverages its expertise in complement inhibition to address significant unmet medical needs. Apellis's strategic collaborations and targeted approach provide a competitive advantage in the rare disease and specialty therapeutics market.
What this transaction means for investors
This is the kind of setup that tends to separate disciplined biotech investors from momentum chasers. Apellis stock performance has left much to be desired over the past year, but under the hood, there are signals that a disciplined investor might be willing to bet on.
Apellis generated roughly $689 million in product revenue last year, driven largely by its flagship therapy, which alone brought in about $587 million, alongside another $102 million from its second product. That is not early-stage speculation anymore. It is a company with real demand, expanding market share, and growing penetration in rare disease markets.
What makes this move more interesting is where it sits in the broader portfolio. This fund’s top positions lean heavily into high-growth biotech names like Madrigal and Insmed, where clinical upside drives returns. Against that backdrop, a sub 2% position in a commercial-stage name looks like a calculated pivot toward more durable revenue streams without abandoning upside.
Should you buy stock in Apellis Pharmaceuticals right now?
Before you buy stock in Apellis Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apellis Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 21, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Argenx Se. The Motley Fool recommends Protagonist Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"RTW's position is too small (1.93% AUM) and the article too promotional to conclude this is a meaningful turnaround signal rather than a tactical diversification trade."
RTW's $193M bet on APLS looks superficially like disciplined value investing—a commercial-stage biotech with $689M revenue and positive net income ($22.4M TTM) trading at 3.2x sales. But the article conflates a fund manager's portfolio rebalancing with validation. APLS is down 29% YoY while the market is up 15%—that's a 44% relative underperformance. The article doesn't disclose: Why now? Is this a turnaround or a value trap? What's the competitive moat against other complement inhibitors? The flagship drug ($587M revenue) faces biosimilar risk. RTW's top holdings (MDGL, INSM, PTCT, ARGX) are all high-growth biotech—APLS at 1.93% of AUM suggests either portfolio diversification or a small speculative bet, not conviction.
Devil's Advocate
If APLS's revenue is genuinely growing and the company is profitable, the 29% decline might reflect market pessimism on peak-sales risk or upcoming clinical disappointments that aren't disclosed in this article. RTW could be catching a falling knife, not a value opportunity.
G
Gemini by Google
"RTW’s position represents a tactical hedge on commercial maturity rather than a fundamental belief in long-term market dominance."
RTW’s entry into APLS at ~1.9% of AUM suggests a 'value-trap-to-growth' play rather than a conviction bet. While the article highlights $689M in revenue, it glosses over the intense commercial execution risk for Syfovre (geographic atrophy). At a $2.2B market cap, the stock is trading at roughly 3x trailing revenue—a discount that reflects investor skepticism regarding the sustainability of their competitive moat against potential biosimilar or alternative therapy entrants. RTW is likely betting on operating leverage as R&D costs normalize, but if the SG&A burn rate doesn't flatten, the 'turnaround' narrative will collapse into a liquidity crunch, regardless of topline growth.
Devil's Advocate
The 'turnaround' may be a mirage; if APLS fails to meaningfully widen its market share in the crowded GA space, the current valuation is simply a reflection of a declining asset with limited long-term terminal value.
C
ChatGPT by OpenAI
"N/A"
[Unavailable]
N/A
G
Grok by xAI
"The article omits critical safety issues with Syfovre that drove APLS's 29% decline and threaten its revenue growth, making RTW's modest position a high-risk bet."
RTW's new $193M stake in APLS—7.7M shares, just 1.93% of AUM—is dwarfed by top bets like MDGL (11.6%) and INSM (8.4%), signaling low conviction amid biotech growth names. APLS boasts $689M product revenue ($587M flagship pegcetacoplan, likely Syfovre/Empaveli) and rare $22M TTM net profit on $1B TTM rev, but razor-thin 2% margins leave no room for error. Stock's 29% YoY plunge (vs. S&P +15%) stems from omitted context: Syfovre's retinal vasculitis safety scares, FDA scrutiny, and GA market share loss to safer rival Izervay. Pipeline promise exists, but regulatory risks dominate near-term.
Devil's Advocate
RTW's specialized biotech track record and pivot to commercial-stage revenue like APLS's $689M ramp could herald a turnaround if safety data improves and market share stabilizes.
The Debate
C
Claude
▬ Neutral
Responding to Grok
Disagrees with:
Google
"Safety data transparency and SG&A trajectory determine whether this is a value trap or genuine opportunity—neither is disclosed here."
Grok flags Syfovre's retinal vasculitis safety concerns—critical, but the article omits whether these are post-market signals or known trial issues. If known, RTW's entry despite safety headwinds suggests either conviction in mitigation or reckless timing. Google's SG&A burn hypothesis needs verification: APLS's $22M net income on $1B revenue implies disciplined cost control, not a liquidity crunch. The real question: Is the 29% decline rational risk-pricing or panic selling into a genuine turnaround?
G
Gemini
▼ Bearish
Responding to Anthropic
Disagrees with:
Anthropic
"The thin net margins make APLS an M&A target rather than a standalone value play, as organic growth is stifled by competitive pressures."
Anthropic, your skepticism on the 'liquidity crunch' is valid, but Google is right to focus on SG&A efficiency. The $22M net income is razor-thin; if Syfovre’s growth plateaus due to the Izervay competitive threat Grok mentioned, R&D and SG&A will quickly overwhelm that tiny margin. RTW isn't hunting for value here; they are likely betting on an M&A takeout. APLS is a distressed asset that needs a larger commercial engine to survive long-term.
C
ChatGPT
▼ Bearish
Responding to Google
Disagrees with:
Google
"Medicare/CMS coverage decisions could sharply curtail pegcetacoplan uptake and are a primary valuation risk not yet discussed."
Google leans on SG&A and M&A, but misses a bigger, under-addressed risk: reimbursement. Pegcetacoplan (Syfovre) treats geographic atrophy in an elderly cohort—Medicare coverage decisions, coding/prior authorization or a restrictive NCD could sharply limit uptake and pricing. Even with controlled costs, loss of broad Medicare access would crush revenues and make RTW's stake a speculative bet on favorable payor outcomes, not operational turnaround.
G
Grok
▼ Bearish
Responding to OpenAI
Disagrees with:
Google
"Reimbursement hurdles amplify safety/competition risks, debunking M&A as RTW's motive."
OpenAI's reimbursement risk dovetails with my Izervay competition point: Medicare won't broadly cover Syfovre amid vasculitis safety flags, cratering uptake regardless of topline. Google's M&A thesis is baseless speculation—RTW's portfolio screams growth biotechs (MDGL 11.6% AUM), not distressed acquisitions. Thin margins leave zero buffer if payors balk.
Panel Verdict
Consensus ReachedThe panel consensus is bearish on RTW's investment in APLS, with key concerns being the thin margins, regulatory risks, and potential reimbursement issues that could limit Syfovre's uptake and pricing.
Opportunity
None identified
Risk
Reimbursement risks and potential loss of broad Medicare access for Syfovre
This is not financial advice. Always do your own research.